{"filings":[{"id":2006716,"accession_number":"0001193125-26-329570","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-08-03T12:03:40+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics reports Q2 net loss of $20.2M; modifies RESTORE-FA trial, delays FECD data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.2M for Q2 2026; cash and securities of $207.4M at quarter-end.","RESTORE-FA trial modified: 12-week cohort at 1 mpk, primary endpoint endogenous FXN protein change; data expected Q1 2027.","Phase 1 MAD trial of DT-818 in DM1 initiated; data expected in 2027.","Phase 2 FECD trial of DT-168 delayed to 2027 due to supply issue with eye droppers.","Registrational plan update expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":999924,"accession_number":"0001193125-26-267485","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-06-11T20:05:08+00:00","items":["5.07"],"status":"ready","headline":"Design Therapeutics stockholders elect director, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Simeon George, M.D., elected Class II director; 29,205,208 votes for, 7,608,724 withheld, 13,264,883 broker non-votes.","Ernst & Young ratified as independent auditor for FY 2026; 50,077,708 votes for, 201 against, 906 abstentions.","Record date April 14, 2026; 62,441,429 shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":482079,"accession_number":"0001193125-26-227875","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-05-18T11:15:07+00:00","items":["8.01"],"status":"ready","headline":"Design Therapeutics reports positive Phase 1/2 data for DT-216P2 in Friedreich ataxia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["After 4 weeks at 1 mpk, mFARS improved 6.4 points, Upright Stability Score 2.7 points, fatigue >5 points (PROMIS).","Whole blood FXN mRNA increased 65% (p<0.001); muscle FXN mRNA up 42% (p=0.015); FXN protein increased 22-27%.","DT-216P2 well-tolerated; no serious adverse events or discontinuations; mild-moderate transient ALT elevations in 3 patients.","Company plans to pursue registrational path; update expected in Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95628,"accession_number":"0001193125-26-187012","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Design Therapeutics Q1 net loss $17.6M; cash $222.8M funds ops into 2029; pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.6M for Q1 2026; R&D expense $14.4M, G&A $5.3M.","Cash, equivalents and securities total $222.8M as of March 31, 2026, providing runway to 2029.","DT-216P2 Phase 1/2 RESTORE-FA trial dosing continues; frataxin update expected H2 2026.","DT-168 Phase 2 FECD trial ongoing with data in H2 2026; DT-818 DM1 Phase 1 MAD trial to begin dosing H1 2026.","David Shapiro, M.D., appointed to board of directors in March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95627,"accession_number":"0001193125-26-137861","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Design Therapeutics appoints Dr. David Shapiro to Board as Class III director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. David Shapiro appointed to Board effective Mar 31, 2026, as Class III director with term through 2027 annual meeting.","Receives annual cash retainer of $40k for Board service and $5k for Nominating Committee service.","Received initial option grant of 60k shares (3-year monthly vest) and prorated annual option of 7.5k shares (1-year vest).","Also appointed to the Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108829,"accession_number":"0001193125-26-098474","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics reports Q4 2025 net loss of $16.0M; cash $219.8M funds operations into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net loss $69.8M; R&D expenses $59.1M, G&A $20.3M.","Cash, equivalents and securities $219.8M as of Dec 31, 2025; runway into 2029.","DT-216P2 (FA) RESTORE-FA trial ongoing; frataxin data expected H2 2026.","DT-168 (FECD) Phase 2 biomarker trial data anticipated H2 2026.","DT-818 (DM1) Phase 1 MAD trial dosing expected H1 2026; results in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108828,"accession_number":"0001193125-26-031772","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Design Therapeutics board member Deepa Prasad resigns effective Feb 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deepa Prasad resigned from Design Therapeutics Board of Directors effective February 1, 2026.","Resignation due to conflict-avoidance policies associated with her new role at a major bank.","No replacement or other board changes announced; remaining directors continue in office."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125276,"accession_number":"0001193125-25-266933","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics plans DT-818 DM1 trial H1 2026; Q3 net loss $17M; cash $206M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["DT-818 nominated as DM1 development candidate; >90% reduction in toxic RNA foci in preclinical studies.","Ex-US regulatory clearance obtained; Phase 1 MAD trial in Australia to start H1 2026; splicing data expected 2027.","Q3 2025 net loss $17.0M; R&D expense $14.6M; G&A expense $4.7M.","Cash and securities $206.0M as of Sept 30, 2025, supporting pipeline advancement.","Board appointed Justin Gover (former CEO of GW Pharma, led $7B acquisition by Jazz) in September 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142002,"accession_number":"0001807120-25-000004","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Design Therapeutics director resigns; Justin Gover appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Arsani William, M.D. resigned from board effective Sept 9, 2025, not due to any disagreement.","Board appointed Justin Gover as Class III director with term ending at 2027 annual meeting.","Gover also named chair of Compensation Committee.","Gover receives annual cash retainers of $40,000 for board service and $12,000 as committee chair.","Gover granted initial option for 30,000 shares vesting over 3 years and prorated grant of 15,833 shares vesting over 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142001,"accession_number":"0000950170-25-105008","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Design Therapeutics Q2 net loss $19.1M; FDA clinical hold on DT-216P2 US IND; cash $216.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.1M for Q2 2025; R&D expense $15.7M, G&A $5.8M; cash and securities $216.3M as of June 30, 2025.","Early human PK data for DT-216P2 shows favorable translation from NHPs; improved AUC and sustained plasma levels vs DT-216P1.","FDA placed clinical hold on DT-216P2 US IND over starting dose; company plans to address with clinical/nonclinical data; RESTORE-FA trial continues outside US.","Phase 2 biomarker trial of DT-168 in Fuchs Endothelial Corneal Dystrophy patients has been initiated.","Preclinical DM1 program on track for development candidate selection in H2 2025; Huntington's disease preclinical characterization ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159958,"accession_number":"0000950170-25-085380","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Design Therapeutics stockholders elect directors and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Heather Berger, Ph.D., Rodney Lappe, Ph.D., and John Schmid elected as Class I directors to serve until 2028 annual meeting.","Rodney Lappe received 32,799,677 votes for, 9,948,461 withheld, indicating notable opposition.","Ernst & Young LLP ratified as independent auditor for FY2025 with 53,577,053 votes for, 2,731 against, 1,795 abstentions.","A total of 56,768,678 shares were outstanding and entitled to vote as of the April 15, 2025 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159957,"accession_number":"0000950170-25-065613","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q1 net loss $17.7M; cash $229.7M funds into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $15.4M, G&A $5.0M for Q1 2025; net loss $17.7M.","Cash and securities $229.7M as of March 31, 2025; expected runway into 2029.","Phase 1 SAD trial ongoing for DT-216P2 (FA); MAD patient study planned mid-2025.","Favorable Phase 1 data for DT-168 (FECD); Phase 2 biomarker trial planned H2 2025.","Appointed Chris Storgard, M.D., as Chief Medical Officer in April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178293,"accession_number":"0000950170-25-035909","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q4 2024 net loss $13.7M; cash $245.5M; FA and FECD trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.7M for Q4 2024 and $49.6M for full year 2024; R&D expense $44.4M, G&A $18.0M.","Cash, equivalents and securities $245.5M as of Dec 31, 2024; expected funding into 2029.","FA program: Phase 1 single ascending dose trial of DT-216P2 initiated; patient dosing expected mid-2025.","FECD program: DT-168 Phase 1 dosing complete; data on track for H1 2025; observational study enrolled ~250 patients.","DM1 development candidate selection expected in 2025; HD preclinical work ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178292,"accession_number":"0000950170-25-004612","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Design Therapeutics updates corporate presentation with no material new information","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation filed as Exhibit 99.1 for use in investor meetings.","No financial results, clinical data, or guidance changes disclosed in the filing.","Filing includes only the presentation; no other material events reported.","This is a routine Regulation FD disclosure without specific new facts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194942,"accession_number":"0000950170-24-123289","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q3 net loss $13.0M; FECD Phase 1 trial initiated, data H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.0M for Q3 2024; R&D expense $11.9M, G&A expense $4.4M.","Cash and securities $254.1M as of Sep 30, 2024; expected to fund operations into 2029.","FECD DT-168 Phase 1 trial initiated in healthy volunteers; initial data expected H1 2025.","FA DT-216P2 Phase 1 single ascending dose study in healthy volunteers on track for H1 2025.","Preclinical programs advancing toward development candidate selection in HD and DM1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211231,"accession_number":"0000950170-24-090332","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q2 net loss $11.8M; cash $261M; FA and FECD programs on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.8M for Q2 2024; R&D expense $10.5M, G&A expense $4.5M.","Cash, cash equivalents and marketable securities $261.0M as of June 30; runway into 2029.","FA program DT-216P2 on track to start patient trials in 2025 after GLP studies complete.","FECD program DT-168 to begin Phase 1 in healthy volunteers in 2024; 200-patient observational study ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229786,"accession_number":"0000950170-24-074243","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Design Therapeutics stockholders elect Pratik Shah as Class III director, ratify EY auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pratik Shah, Ph.D. elected as Class III director with ~42.8M votes for, ~3.5M withheld (7.7M broker non-votes).","Ernst & Young LLP ratified as independent auditor for FY2024 (53,981,806 for, 2,764 against, 2 abstentions).","Annual Meeting held June 13, 2024; 56,495,039 shares outstanding and entitled to vote as of record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229785,"accession_number":"0000950170-24-055645","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q1 net loss $11.1M; cash $270.7M; advancing DT-216P2, DT-168, HD, DM1 programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.1M for Q1 2024; R&D expenses $9.8M, G&A expenses $4.6M.","Cash and securities $270.7M as of March 31, 2024; expected funding into 2029.","DT-216P2 for Friedreich Ataxia: GLP studies by year-end 2024; patient trials start 2025.","DT-168 for FECD: Phase 1 development expected to start in 2024; observational study enrolling 200 patients.","GeneTAC pipeline: HD and DM1 programs advancing toward development candidates; preclinical data showed mutant gene knockdown."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248275,"accession_number":"0000950170-24-033475","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics reports $281.8M cash, new FA drug product DT-216P2, IND cleared for DT-168, new HD program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.8M in Q4 2023 and $66.9M for full year; cash & securities $281.8M funding 5-year runway.","New FA drug product DT-216P2 shows >10-fold improved PK and favorable injection site safety; GLP studies to complete by year-end 2024 for patient trials in 2025.","FDA cleared IND for DT-168 in FECD; Phase 1 to start in 2024; observational study of 200 patients underway.","New HD program targeting mutant HTT shows >50% selective reduction in brain striatum in preclinical studies.","DM1 GeneTAC molecules potently dial-down mutant DMPK, restore splicing; working toward development candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265769,"accession_number":"0000950170-23-062937","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics reports Q3 net loss of $15.8M, extends cash runway to 5 years, appoints Pratik Shah as CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.8M for Q3 2023; R&D expenses $13.3M, G&A expenses $5.6M.","Cash and securities of $290.9M as of Sep 30, 2023, expected to fund operations through at least 2028.","Strategic realignment initiated to prioritize long-term growth, focus capital, and implement cost savings.","Pratik Shah appointed as Chief Executive Officer, leading company turnaround and portfolio review.","Comprehensive corporate and pipeline update planned for early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282995,"accession_number":"0001193125-23-221586","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Design Therapeutics CEO Siffert resigns; Chair Shah appointed CEO, receives stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["João Siffert resigned as President/CEO/principal financial officer effective Aug 25, 2023; employee status ends Sept 1, 2023.","Pratik Shah, Ph.D., Board Chair, appointed President, CEO and principal financial officer effective Aug 25, 2023; Simeon George named lead independent director.","Siffert receives 12-month salary continuation, $230,220 prorated bonus, 12-month COBRA, extended option exercisability (6 months).","Shah granted options: 1,050,000 shares time-vesting; 525,000 shares contingent on FA IND clearance; 525,000 shares contingent on FA Phase 2a start."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282994,"accession_number":"0000950170-23-042392","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Reports Q2 2023 Results, Pipeline Progress with DT-216 and DT-168","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Initial Phase 1 data for DT-216 in Friedreich Ataxia showed significant dose-related FXN mRNA increase in skeletal muscle (p<0.05)","DT-216 Phase 1 MAD trial resumed in H2 2024 with improved formulation, data expected H1 2025","IND submission for DT-168 for Fuchs Endothelial Corneal Dystrophy on track for H2 2023","Cash and securities of $303.1M as of June 30, 2023, expected to fund operations through 2026","Net loss of $19.9M for Q2 2023; R&D expenses $17.1M, G&A $5.5M"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302352,"accession_number":"0001193125-23-159009","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2023-06-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Design Therapeutics shareholders re-elect three directors, ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class II directors re-elected: Simeon George (47.5M for), Arsani William (49.0M), Deepa Prasad (49.0M); broker non-votes ~3.35M.","Ratification of Ernst & Young as independent auditor for FY2023 approved: 52.5M for, 437 against, 123,262 abstentions.","Annual meeting held May 31, 2023; 55,945,551 shares outstanding as of record date April 3, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302351,"accession_number":"0000950170-23-019682","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics reports Q1 2023 net loss of $19.3M; cash $315.4M; Phase 1 MAD data for DT-216 expected in Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.3M for Q1 2023; R&D expenses $15.7M, G&A expenses $5.9M.","Cash, equivalents and marketable securities $315.4M, expected to fund operations through 2025.","Initial Phase 1 multiple-ascending dose trial data for DT-216 in Friedreich ataxia expected Q3 2023.","IND submission for DT-168 eye drop for FECD on track for H2 2023; preclinical data presented at ARVO 2023.","IND submission for DM1 GeneTAC program on track for H2 2024; development candidate selection underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322015,"accession_number":"0000950170-23-007864","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q4 net loss $17.3M; FY2022 net loss $63.3M; cash $330M; DT-216 MAD data mid-2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["R&D expenses $14.3M (Q4) and $48.6M (FY2022); G&A $5.1M (Q4) and $19.0M (FY2022).","Cash, equivalents and securities $330.4M as of Dec 31, 2022; expected runway through 2025.","Phase 1 MAD trial of DT-216 for Friedreich Ataxia ongoing; initial data expected mid-2023, final by year-end.","IND submission for DT-168 (FECD) planned H2 2023; DM1 program targeting IND in 2024.","No revenue reported; net loss driven by R&D investment in clinical and preclinical pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340087,"accession_number":"0000950170-22-021862","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics reports Q3 net loss $17.7M; cash $344.2M; DT-216 Phase 1 SAD data in Dec 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.7M for Q3 2022; R&D expenses $14.3M, G&A expenses $4.9M.","Cash, equivalents and securities of $344.2M as of Sept 30, 2022, supporting multi-year runway.","Initial data from DT-216 single-ascending dose Phase 1 for Friedreich Ataxia expected Dec 2022.","Multiple-ascending dose Phase 1 dosing initiated; completion anticipated mid-2023.","DM1 GeneTAC program preclinical; clinical development expected to begin in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357378,"accession_number":"0000950170-22-015520","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics reports Q2 net loss $15M; holds $359.4M cash; initial FA data expected Q4 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.0M for Q2 2022; R&D expenses $11.3M; G&A expenses $4.3M.","Cash, equivalents and securities totaled $359.4M as of June 30, 2022, providing multi-year runway.","Initial Phase 1 single-ascending dose data for DT-216 in Friedreich ataxia expected Q4 2022.","Clinical development for myotonic dystrophy type-1 GeneTAC program anticipated in 2023.","Preclinical FECD program advancing; molecules showed nearly complete reduction in toxic RNA foci in vitro."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375980,"accession_number":"0000950170-22-011751","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Design Therapeutics stockholders elect three directors, ratify EY as auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Heather Berger, Rodney Lappe, and John Schmid as Class I directors to serve until 2025.","Votes for Berger: 49,858,607; for Lappe: 49,543,074; for Schmid: 49,344,059; with ~1.94M broker non-votes each.","Ratification of Ernst & Young as independent auditor for FY2022 passed with 53,181,814 votes for, 542 against, 36 abstentions.","Meeting held June 15, 2022; 55,781,681 shares outstanding and entitled to vote as of record date April 18, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375979,"accession_number":"0000950170-22-008486","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q1 net loss $13.3M; cash $371.2M; DT-216 Phase 1 underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.3M for Q1 2022; R&D expenses $8.8M, G&A $4.6M.","Cash, cash equivalents and marketable securities of $371.2M as of March 31, 2022.","DT-216 Phase 1 single-ascending dose trial in Friedreich ataxia patients; topline data expected H2 2022.","DT-216 received FDA Fast Track designation for FA.","Preclinical data for Fuchs endothelial corneal dystrophy GeneTAC molecules showed up to 99% reduction in toxic RNA foci."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394310,"accession_number":"0000950170-22-004311","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Design Therapeutics expands office/lab space by 4,900 sq ft via related-party lease amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leases additional 4,900 sq ft in Carlsbad building; total leased space ~17,270 sq ft.","Annual base rent for expansion initially ~$132,000, with 3% increases; rent abated through June 15, 2022.","Expansion term runs to August 31, 2027, coterminous with existing lease.","Landlord Crossing Holdings LLC controlled by Design's Executive Chair Pratik Shah (related-party transaction).","Possession expected by July 1, 2022; delay penalty of one day rent abatement per day, up to 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394309,"accession_number":"0000950170-22-003356","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics reports FY2021 net loss $35.5M, IND cleared for DT-216 Phase 1 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $35.5M for FY2021 ($11.1M in Q4); cash and investments $384.1M at Dec 31, 2021.","IND for DT-216 (Friedreich Ataxia) cleared by FDA; Phase 1 trial to begin shortly.","Appointed Dr. Jae Kim as Chief Medical Officer to lead clinical development.","Preclinical data on GeneTAC molecules for Fuchs endothelial corneal dystrophy to be presented at ARVO May 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412892,"accession_number":"0000950170-21-003747","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics reports Q3 2021 net loss $11.3M; FA program on track for H1 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.3M for Q3 2021; R&D expenses $8.5M, G&A $2.8M.","Cash, cash equivalents and securities total $393.7M as of Sept 30, 2021.","FA GeneTAC candidate on track for Phase 1 initiation in H1 2022; topline data expected in 2022.","DM1 program: preclinical data show near-complete resolution of foci; clinical start planned for 2023.","Company to present at Piper Healthcare Conference Nov 30 – Dec 2, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431562,"accession_number":"0001193125-21-252071","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2021-08-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Design Therapeutics appoints Julie Burgess as Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julie Burgess appointed Chief Accounting Officer, effective September 13, 2021.","Annual base salary of $350,000, bonus up to 35%, and stock option for 135,000 shares.","Burgess previously SVP Finance at Otonomy; brings over 25 years of experience.","Dawn Giangiulio will cease as interim principal accounting officer but remain Controller."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431561,"accession_number":"0001564590-21-042617","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Design Therapeutics Q2 net loss $7.6M; FA GeneTAC on track for H1 2022 clinical start","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.6M; R&D expenses $5.0M, G&A $2.7M; cash & investments $402.8M.","Lead FA GeneTAC program: IND-enabling data support initiation of Phase 1 trial in H1 2022.","Appointed Elizabeth Gordon, Ph.D., as SVP Regulatory Affairs; board expanded with Behanna & Prasad.","DM1 GeneTAC program preclinical data planned for H2 2021.","Well-tolerated FA GeneTAC doses in rodents/NHPs achieved CNS, heart, muscle concentrations above therapeutic threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431560,"accession_number":"0001193125-21-239304","cik":1807120,"company_name":"Design Therapeutics, Inc.","ticker":"DSGN","form_type":"8-K","filed_at":"2021-08-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Design Therapeutics VP Finance Resigns; Controller Appointed Interim Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin Thacker resigned as VP Finance and principal accounting officer effective August 13, 2021.","Dawn Giangiulio, Controller since April 2020, appointed interim principal accounting officer effective August 13, 2021.","Giangiulio also serves as Controller of ARS Pharmaceuticals on a part-time basis, resigning September 3, 2021.","Previously, Giangiulio was Senior Manager R&D Finance at Teva Pharmaceutical Industries from 2015 to 2020.","Giangiulio is a licensed CPA and began her career at PricewaterhouseCoopers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":668914215.2756757,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}